Face taping promises smoother skin and fewer wrinkles without injectables, but evidence suggests any visible benefits are largely temporary.
News|Podcasts|June 5, 2024
The Cutaneous Connection: From Infection to Innovation - The Turn Therapeutics Story
Author(s)Emma Andrus, Associate Editor
Listen
0:00 / 0:00
Turn Therapeutics' Bradley Burnam recently spoke with Dermatology Times.
Advertisement
In this episode of The Cutaneous Connection, Bradley Burnam, the founder and CEO of
Like this podcast, have suggestions, or want to participate in future episodes? Contact our team at
Advertisement
Related to this article
The September issue highlights advances in alopecia areata, cosmetic SPF, psoriasis treatment, teledermatology, and atopic dermatitis.
Two-year oral IL-23 data, GLP-1 biomarker findings, and a nonsurgical option for superficial basal cell carcinoma headline the sessions covered in Las Vegas.
A retrospective claims analysis of 2897 matched pairs found hazard ratios of 0.48 to 0.67 for new atopic disease with dupilumab vs systemic corticosteroids in children.
Castor oil has become a popular social media remedy for thicker, longer hair, but evidence supporting its ability to stimulate hair growth remains limited.
SYX-5219 improved disease severity and itch in a Phase 1b trial of adults with moderate to severe atopic dermatitis.
Can “Botox in a bottle” really rival injectable neuromodulators? We examine the evidence behind topical peptide serums and Argireline.
Christophe Piketty discusses 3-year ARCADIA data demonstrating sustained efficacy and long-term safety of nemolizumab in atopic dermatitis.
Advertisement
Advertisement